Pfizer (PFE) Given a $45.00 Price Target at Morgan Stanley

Share on StockTwits

Pfizer (NYSE:PFE) has been assigned a $45.00 target price by stock analysts at Morgan Stanley in a note issued to investors on Thursday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price objective suggests a potential upside of 6.64% from the company’s current price.

A number of other research firms have also recently weighed in on PFE. Cantor Fitzgerald set a $45.00 price target on Pfizer and gave the stock a “buy” rating in a report on Monday, August 27th. Deutsche Bank set a $45.00 price target on Pfizer and gave the stock a “buy” rating in a report on Tuesday, August 21st. JPMorgan Chase & Co. reiterated a “buy” rating and set a $42.00 price target on shares of Pfizer in a report on Thursday, August 23rd. Barclays increased their price target on Pfizer from $38.00 to $40.00 and gave the stock a “neutral” rating in a report on Thursday, August 23rd. Finally, BMO Capital Markets reiterated a “buy” rating and set a $44.00 price target on shares of Pfizer in a report on Monday, August 27th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have issued a buy rating to the company’s stock. Pfizer presently has an average rating of “Hold” and an average price target of $41.89.

NYSE PFE opened at $42.20 on Thursday. The firm has a market cap of $249.13 billion, a PE ratio of 15.92, a price-to-earnings-growth ratio of 2.01 and a beta of 0.96. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.16 and a quick ratio of 0.91. Pfizer has a twelve month low of $33.20 and a twelve month high of $42.77.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, July 31st. The biopharmaceutical company reported $0.81 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.07. The business had revenue of $13.47 billion during the quarter, compared to analysts’ expectations of $13.30 billion. Pfizer had a return on equity of 25.35% and a net margin of 42.35%. The company’s revenue was up 4.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.67 EPS. equities analysts expect that Pfizer will post 2.99 earnings per share for the current year.

In related news, insider Sally Susman sold 40,381 shares of the firm’s stock in a transaction dated Friday, July 20th. The stock was sold at an average price of $37.22, for a total transaction of $1,502,980.82. Following the completion of the transaction, the insider now directly owns 155,377 shares in the company, valued at approximately $5,783,131.94. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Laurie J. Olson sold 10,214 shares of the firm’s stock in a transaction dated Monday, August 13th. The shares were sold at an average price of $41.00, for a total value of $418,774.00. Following the transaction, the insider now owns 72,672 shares of the company’s stock, valued at $2,979,552. The disclosure for this sale can be found here. Insiders have sold a total of 761,230 shares of company stock valued at $29,054,690 over the last 90 days. 0.06% of the stock is currently owned by company insiders.

A number of hedge funds have recently bought and sold shares of the business. BlackRock Inc. raised its position in Pfizer by 1.5% in the 1st quarter. BlackRock Inc. now owns 459,530,944 shares of the biopharmaceutical company’s stock valued at $16,308,754,000 after purchasing an additional 6,785,335 shares in the last quarter. Bank of New York Mellon Corp raised its position in Pfizer by 11.9% in the 4th quarter. Bank of New York Mellon Corp now owns 70,738,885 shares of the biopharmaceutical company’s stock valued at $2,562,162,000 after purchasing an additional 7,534,957 shares in the last quarter. Geode Capital Management LLC raised its position in Pfizer by 3.1% in the 4th quarter. Geode Capital Management LLC now owns 63,123,777 shares of the biopharmaceutical company’s stock valued at $2,281,563,000 after purchasing an additional 1,881,570 shares in the last quarter. Massachusetts Financial Services Co. MA raised its position in Pfizer by 0.3% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 61,881,280 shares of the biopharmaceutical company’s stock valued at $2,245,053,000 after purchasing an additional 160,730 shares in the last quarter. Finally, Morgan Stanley raised its position in Pfizer by 2.5% in the 2nd quarter. Morgan Stanley now owns 54,367,234 shares of the biopharmaceutical company’s stock valued at $1,972,442,000 after purchasing an additional 1,345,528 shares in the last quarter. 69.12% of the stock is currently owned by institutional investors.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Read More: Trading Strategy Methods and Types

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply